BioNTech SE (22UA) — Cash Flow Quality Index
BioNTech SE (22UA) has a Cash Flow Quality Index of -1.79x as of December 2024. Operating cash flow of €-463.30 Million is below net income of €259.50 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore BioNTech SE strategic investment ratio to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BioNTech SE Cash Flow Quality Index (2020–2023)
Historical Cash Flow Quality Index for BioNTech SE across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check tangible equity quality of BioNTech SE to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for BioNTech SE (2020–2023)
Year-by-year earnings quality comparison for BioNTech SE. For live market cap and the full company financial profile, see market value of BioNTech SE.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 5.77x | €5.37 Billion | €930.30 Million | ▲ +301.2% |
| 2022 | 1.44x | €13.58 Billion | €9.43 Billion | ▲ +1564.9% |
| 2021 | 0.09x | €889.70 Million | €10.29 Billion | ▲ +109.7% |
| 2020 | -0.89x | €-13.50 Million | €15.20 Million | — |